We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Scancell Holdings Plc | LSE:SCLP | London | Ordinary Share | GB00B63D3314 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 10.10 | 9.70 | 10.50 | 10.10 | 10.10 | 10.10 | 177,070 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 5.27M | -11.94M | -0.0129 | -7.83 | 93.71M |
Date | Subject | Author | Discuss |
---|---|---|---|
03/5/2023 13:30 | What a little hero IF only it were true .... Money does not equate to happiness, or time well spent Not that matters to YOU as someone who has NONE of the above ..... I am just taking a break from being outdoors,(31 C in the sun, clear blue/fresh clean air, Bee Eaters flying /chattering overhead) trimming branches from trees grown on 'our' land... prior to cutting into logs 50/60 cm lengths to stack in the sun to dry-out for future log burner fuel. .... IF YOU were half as CONtent/happy as me, I would STILL be twice as CONtent/happy as YOU .... YOU think YOU know everything, when YOU really know NOTHING | the real lozan | |
03/5/2023 12:10 | sadly lozan my money is actually invested in Scancell via OO to try and stop "Dead" patients from something called Cancer .... you on the other hand together with "Gerald" the accomplice are doing everything possible to subvert that Goal Sadly for you Scancell is winning the battle ..... but you will always be remembered for being that Grubby little Hermit who ran away from the real world to set up his clandestine operations knowing that the locals consistently bury there heads in the sand to any economic reality .... and when you have no money ..... something follows .... Yes, You have no shares How is your health .... still no mention of "walking jo" or scrumping must be two years now | inanaco | |
03/5/2023 11:08 | "RELIABLE" = As per usual, HE draws attention to his EGOdriven FAILURES by mentioning an item HE knows NOTHING about, and an item ("RELIABLE") HE certainly = is NOT Unless - Dead money,getting SPIKED,FAILED FALSE CLAIMS/LIES etc. are deemed something to be desired. | the real lozan | |
03/5/2023 10:34 | Lozans Clock .... so reliable keeps perfect time | inanaco | |
03/5/2023 09:50 | P7 - Spot on A case of the ill informed trHYPE brainwasher revealing HE is ignorant The Boris brainwasher being brainwashed REALITY "Lozans Life ... the real France" I spent yesterday 'mawn lowing' around patches of different Orchids ,,, a joy to behold....A lifestyle totally diverse from the landan mentality The locals, of all ages here engage in peaceful protest = AGAINST the LOSS/STEALING of THEIR RIGHTS by the DICTATORS of world slave makers. The world is at WAR for FREEDOM..Macron's own words some time ago No one needs the ranting of UNRELIABLE ignorant trHYPE merchants,,, who have already 'Given in' | the real lozan | |
03/5/2023 09:26 | Morning "Gerald" | inanaco | |
03/5/2023 08:38 | telegraph sadly ..... when you look out from Lozan Towers .... the grass today maybe green but by the summer its NOT ........ 40c plus suitable only for reptiles ... | inanaco | |
03/5/2023 08:35 | The figures on France’s debt levels are alarming. Total government debt has risen to 112pc of GDP, in contrast to around 66pc in Germany and 100pc in the UK. And it's rising with every year that passes. Its government debt has surpassed Italy, in absolute terms, if not as a percentage of GDP, and it is now the third most indebted country in the world after the United States and Japan. All that debt is mostly owed to the rest of the world. Indeed, according to figures from the Banque de France from 2021, France by itself accounts for 8.1pc of global debt liabilities, second only to the US, and almost twice the level of Japan. And much of the borrowing is used to support a nation where government expenditure as a proportion of GDP hit 59pc in 2021. The higher this figure rises, the more it will crush the life out of private enterprise. | inanaco | |
03/5/2023 08:33 | Lozans Life ... the real France Labour day strikes The trouble is, this may not be the worst of Macron's challenges. Last week, the ratings agency Fitch downgraded France’s debt, the first major de-rating of a developed economy in years. And that is just the start. France is now caught in a doom-loop, where even perfectly sensible reforms trigger a wave of protests, forcing yet more downgrades as the impossibility of change becomes clear, which increases the cost of all the money the state has to keep borrowing. This could end in a full-blown sovereign debt crisis, with Paris at the centre of the storm. | inanaco | |
03/5/2023 08:22 | Bermudashorts GlycotimeToday 08:19 Interesting article below from Ben Schumann, Imperial College/Francis Crick which gives some background and context to the field of glycobiology . Some quotes from the article, followed by one from Scancell- 'perhaps no other field is as understated despite such a heavy clinical impact' ' Why is biomedicine still largely turning a blind eye to glycobiology? In my opinion – because they are difficult to deal with' 'glycotime” is rapidly gaining momentum in therapy and diagnosis' 'We (Scancell) remain one of only a few companies worldwide that has the capability to produce high affinity, humanised anti-glycan antibodies' | marcusl2 | |
03/5/2023 08:22 | I think they are waiting for MHRA clearance for iScib-1. Hopefully soon. | marcusl2 | |
02/5/2023 14:12 | Any ideas on when ISCIB will be entering trials? | octopus100 | |
02/5/2023 13:11 | IF - At 15p to sell,EVEN IF "some big Pharma somewhere would want to do a partnership." WHAT price would "some big Pharma somewhere would want to do a partnership." OFFER ??? | the real lozan | |
02/5/2023 13:05 | Inane, you're amongst the 2%, I assume you are correct and the 98% are wrong. | panama7 | |
02/5/2023 13:03 | TF, only a 2% take up of the spring booster says it all really. By the criteria on here and the other channel that means the 98% are anti-vaxxers. One might deduce that no one will be remotely interested in Covidity which will upset the happy clappers who believe that some big Pharma somewhere would want to do a partnership. | panama7 | |
02/5/2023 10:05 | Thanks Super. | torquayfan | |
02/5/2023 10:03 | tf - not, I don't think, the NHS. Your local trust? | supernumerary | |
02/5/2023 09:02 | I wonder if Pfizer`s $43 B acquisition of Seagen will delay an Avidimab deal if one is in the works ? | marcusl2 | |
02/5/2023 08:50 | Promising activity in CD40 based preclinical models CD40 (cluster of differentiation 40) agonists are a promising area in immunooncology as they increase the number and quality of tumour-infiltrating T cells. Theoretically they should be highly effective as a monotherapy or to reverse resistance to checkpoint-blocking antibodies. However, preclinical potency has not yet been replicated in the clinical setting and none of these mAbs have advanced beyond early trial phases. One of the challenges encountered was insufficient immune activation, which resulted in antitumor efficacy only becoming apparent at toxic doses. SEA-CD40 (Seagen) is in Phase II trials for advanced solid tumours. AvidiMab was used in the Fc region (Exhibit 5) in an IgG1 format, with key residues from murine IgG3 transferred into the human SEA-CD40 IgG1 Fc region. The results for iSEACD40 showed higher Fc-Fc self-association, slower off-rate and improved binding to CD40, and better functional affinity than original SEA-CD40. These findings of better performance were also seen in other immune models that rely on clustering and/or increased residence time for activity. Preclinical work continues to highlight the versatility and broad applicability of the AvidiMab platform, with sizable improvements seen across many applications. | marcusl2 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions